Teva overhauls its board again, and almost all its old-timers are gone

Looks like another scale-down is coming to Teva’s board.

The Israeli drugmaker’s slate of directors, which has changed extensively in recent years at activist investor urging, will shrink by two spots after the company’s annual meeting in June, according to a regulatory filing.